President Donald Trump has nominated Scott Gottlieb, a partner at New Enterprise Associates Inc, to serve as Commissioner of the U.S. Food and Drug Administration. Gottlieb, a physician, most recently served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs.
CHEVY CHASE, Md., March 11, 2017 /PRNewswire/ — New Enterprise Associates, Inc. (NEA) Venture Partner Scott Gottlieb, M.D., has been nominated by President Donald J. Trump to serve as Commissioner of the U.S. Food and Drug Administration (FDA). A physician, policy expert, and champion of health care entrepreneurship and the opportunities enabled by innovation in medical care, Dr. Gottlieb has held senior positions at the FDA and the Centers for Medicare and Medicaid Services. In his most recent government role, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs. He has been a member of NEA’s healthcare investing team since leaving the FDA in 2007.
“Dr. Gottlieb’s unique expertise straddles the intersection of medical care, entrepreneurship, and the role of public policy in facilitating the discovery and development of safe and effective new medical products to patients. He believes in the power of innovation to improve the quality of patient care and has the insight and experience to make it possible,” said David Mott, General Partner and head of NEA’s healthcare investing practice. “Across NEA’s diverse healthcare portfolio, his guidance has proven invaluable to our entrepreneurs and executives. He understands how transformative innovation occurs—not just the development of new medical treatments, but also the central role that patients and medical professionals, entrepreneurs, investors, and capital markets, all play in the life science innovation ecosystem. At NEA, he has been an effective leader, helping guide our portfolio companies as they seek to develop breakthrough advances in medical care.”
Dr. Gottlieb is a frequent contributor to The Wall Street Journal and serves as a resident fellow at the American Enterprise Institute. He also serves as an advisor to the National Coalition for Cancer Survivorship, and is a member of the policy board to the Society of Hospital Medicine. He was appointed by the U.S. Senate to serve on the Federal Health IT Policy Committee.
Earlier in his career, Dr. Gottlieb worked as a healthcare analyst for the investment bank Alex. Brown & Sons. He completed a residency in internal medicine at the Mount Sinai Medical Center in New York and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University, in Middletown, Connecticut, where he studied Economics.
New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With nearly $17 billion in cumulative committed capital since inception NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm’s long track record of successful investing includes more than 200 portfolio company IPOs and more than 350 acquisitions. For more information, visit www.nea.com.